Akero Therapeutics (AKRO)
(Delayed Data from NSDQ)
$48.37 USD
-0.48 (-0.98%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $48.17 -0.20 (-0.41%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Fundamental Charts
About Dividend Yield (TTM)
Akero Therapeutics, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
AKRO 48.37 -0.48(-0.98%)
Will AKRO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AKRO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AKRO
Altimmune Gears Up to Report Q2 Earnings: Here's What to Expect
Amarin Gears Up to Report Q2 Earnings: Here's What to Expect
AKRO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Incyte Gears Up to Report Q2 Earnings: Is a Beat in the Cards?
VKTX Stock Down on Wider-Than-Expected Loss in Q2, Nil Sales
Exelixis' Q2 Earnings: Will Cabometyx Sales Drive Growth?
Other News for AKRO
Altimmune: Potential Tough Road Ahead Amid Fierce Competition (Rating Downgrade)
Insider Sell: Andrew Cheng Sells 30,000 Shares of Akero Therapeutics Inc (AKRO)
Akero Therapeutics’ Efruxifermin Study: A Potential Game-Changer for NASH/MASH Treatment
Logos Global Management LP Acquires 4,800,000 Shares in Arvinas Inc
Akero Therapeutics (AKRO) Emerges as Attractive Acquisition Target | AKRO Stock News